Julie K Bower1, James S Pankow2, Mariana Lazo3, Eric Christenson4, Ron C Hoogeveen5, Christie M Ballantyne5, Marc K Halushka6, Brad C Astor7, Elizabeth Selvin3. 1. Division of Epidemiology, The Ohio State University College of Public Health, Columbus, OH, USA. Electronic address: jbower@jhsph.edu. 2. Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, USA. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA; Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 4. Drexel University School of Medicine, Philadelphia, PA, USA. 5. Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX, USA. 6. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7. Departments of Medicine and Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Abstract
OBJECTIVES: The soluble receptor for advanced glycation end products (sRAGE) has been implicated in the development of diabetes-related vascular complications, but the variability of concentrations of sRAGE in the blood is unknown. The objective of this study was to characterize within-person three-year variability of plasma levels of sRAGE. DESIGN AND METHODS: We measured sRAGE in plasma samples from 179 men and women in the community-based Atherosclerosis Risk in Communities (ARIC) Study at two time points, three years apart. We calculated correlation coefficients and the within-person coefficient of variation (CVw) to characterize variability in sRAGE. We compared these estimates to total cholesterol and white blood cell count (WBC) in the same participants. RESULTS: Mean sRAGE concentrations at the two time points (mean time between measurements = 2.9 years) were 1096.2 pg/mL and 990.2 pg/mL, respectively (mean difference = -106.0 pg/mL, p-value < 0.001). The Pearson's correlation was 0.78 (Spearman's, 0.73). The intra-class correlation coefficient was 0.76 and the CVw was 26.6%. Compared to sRAGE, Pearson's and Spearman's correlations for total cholesterol (0.76 and 0.77) and white blood cell count (0.61 and 0.72) were similar, although CVw for both was lower (8.7% for cholesterol, 15.6% for WBC). Less than 4% of participants' values changed substantially (50% or greater) over the three-year interval. CONCLUSIONS: We observed that sRAGE concentrations remained relatively stable over three years. Our findings suggest that a single measure of circulating sRAGE tracks well in a community-based population and could be a useful measure in clinical and epidemiologic studies of long-term risk.
OBJECTIVES: The soluble receptor for advanced glycation end products (sRAGE) has been implicated in the development of diabetes-related vascular complications, but the variability of concentrations of sRAGE in the blood is unknown. The objective of this study was to characterize within-person three-year variability of plasma levels of sRAGE. DESIGN AND METHODS: We measured sRAGE in plasma samples from 179 men and women in the community-based Atherosclerosis Risk in Communities (ARIC) Study at two time points, three years apart. We calculated correlation coefficients and the within-person coefficient of variation (CVw) to characterize variability in sRAGE. We compared these estimates to total cholesterol and white blood cell count (WBC) in the same participants. RESULTS: Mean sRAGE concentrations at the two time points (mean time between measurements = 2.9 years) were 1096.2 pg/mL and 990.2 pg/mL, respectively (mean difference = -106.0 pg/mL, p-value < 0.001). The Pearson's correlation was 0.78 (Spearman's, 0.73). The intra-class correlation coefficient was 0.76 and the CVw was 26.6%. Compared to sRAGE, Pearson's and Spearman's correlations for total cholesterol (0.76 and 0.77) and white blood cell count (0.61 and 0.72) were similar, although CVw for both was lower (8.7% for cholesterol, 15.6% for WBC). Less than 4% of participants' values changed substantially (50% or greater) over the three-year interval. CONCLUSIONS: We observed that sRAGE concentrations remained relatively stable over three years. Our findings suggest that a single measure of circulating sRAGE tracks well in a community-based population and could be a useful measure in clinical and epidemiologic studies of long-term risk.
Authors: Christin Wittwer; Julia Lehner; Debora Fersching; Barbara Siegele; Oliver J Stoetzer; Stefan Holdenrieder Journal: Anticancer Res Date: 2012-05 Impact factor: 2.480
Authors: Elizabeth Selvin; Marc K Halushka; Andreea M Rawlings; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Brad C Astor Journal: Diabetes Date: 2013-02-08 Impact factor: 9.461
Authors: Casey M Rebholz; Brad C Astor; Morgan E Grams; Marc K Halushka; Mariana Lazo; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Elizabeth Selvin Journal: Nephrol Dial Transplant Date: 2014-08-21 Impact factor: 5.992
Authors: Marta Marin-Oto; David Sanz-Rubio; Fernando Santamaría-Martos; Ivan Benitez; Ana L Simon; Marta Forner; Pablo Cubero; Ana Gil; Manuel Sanchez-de-laTorre; Ferran Barbe; José M Marin Journal: Respir Res Date: 2022-06-21
Authors: Mahmoud Al Rifai; Andrea L C Schneider; Alvaro Alonso; Nisa Maruthur; Christina M Parrinello; Brad C Astor; Ron C Hoogeveen; Elsayed Z Soliman; Lin Y Chen; Christie M Ballantyne; Marc K Halushka; Elizabeth Selvin Journal: J Diabetes Complications Date: 2014-11-25 Impact factor: 2.852
Authors: Mariana Lazo; Marc K Halushka; Lu Shen; Nisa Maruthur; Casey M Rebholz; Andreea M Rawlings; Ron C Hoogeveen; Tina E Brinkley; Christie M Ballantyne; Brad C Astor; Elizabeth Selvin Journal: Am Heart J Date: 2015-08-14 Impact factor: 4.749
Authors: Marci Laudenslager; Mariana Lazo; Dan Wang; Elizabeth Selvin; Po-Hung Chen; James S Pankow; Jeanne M Clark Journal: Dig Liver Dis Date: 2021-02-24 Impact factor: 5.165
Authors: Nisa M Maruthur; Man Li; Marc K Halushka; Brad C Astor; James S Pankow; Eric Boerwinkle; Josef Coresh; Elizabeth Selvin; Wen Hong Linda Kao Journal: PLoS One Date: 2015-06-17 Impact factor: 3.240
Authors: S Goya Wannamethee; Paul Welsh; Olia Papacosta; Elizabeth A Ellins; Julian P J Halcox; Peter H Whincup; Naveed Sattar Journal: Atherosclerosis Date: 2017-07-12 Impact factor: 5.162
Authors: Mitra Nadali; Lovisa Lyngfelt; Malin C Erlandsson; Sofia Töyrä Silfverswärd; Karin M E Andersson; Maria I Bokarewa; Rille Pullerits Journal: Front Med (Lausanne) Date: 2021-01-28